Researchers at the University of Colorado developed a vaccine that left mice immune to weight gain, despite eating a diet ...

Weight loss drugs have risen in popularity in the recent years, but a disconnect remains between those who need the drugs and ...

The newly launched biotech is equipped with rights to a trio of weight loss medicines licensed from China-based Sciwind ...

Maridebart cafraglutide, a novel injectable GIP receptor antagonist/GLP-1 receptor agonist, reduced body weight by ...

Beyond the influence of new therapies on drug pricing trends, Cowen’s report also accounted for the effects of legislation ...

Eli Lilly's popular obesity drug Zepbound can now be covered by government-backed Medicare drug plans, CNBC reported on ...

The drug's development was funded by Novo Nordisk, the maker of popular semaglutide drugs like Ozempic and Wegovy. While these GLP-1 receptor agonists are effective in weight management, they often ...

Variant Bio, a small biotech company based in Seattle, is using genetic information from Indigenous people to develop drugs for obesity and diabetes.

When it comes to weight loss drugs, Ozempic has become a phenomenon. With nearly $14 billion in sales in 2023, it shows no ...

Polls provide a useful window into understanding how Americans view their own weight and the recent availability of drugs ...

If innovative cancer therapies were the top launches to watch in 2024, this year’s high-profile biopharma debuts is slated to ...

Danish drugmaker Novo Nordisk and U.S. tech firm Valo Health said on Wednesday they were expanding their 2023 agreement to ...